Anticancer composition based on anti-angiogenesis medicine

An anti-vascular and composition technology, applied in the field of tumor treatment, can solve the problems such as incomplete effect, not durable, drug resistance and the like

Active Publication Date: 2014-11-05
朱曙东
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, although the growth of the patient's tumor is blocked, the blocking effect is not complete and long-lasting, and drug resistance ensues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer composition based on anti-angiogenesis medicine
  • Anticancer composition based on anti-angiogenesis medicine
  • Anticancer composition based on anti-angiogenesis medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1 Preparation of antitumor pharmaceutical composition

[0017] The formula is as follows:

[0018] Sunitinib 40 mg

[0019] Davacosini 40mg

[0020] 1N HCl 940 µl

[0021] Tween 80 50 microliters

[0022] 5 mL of 50 mM citrate buffer

[0023] 1% polyethylene glycol PEG-300 1ml

[0024] Sterile water Add to total volume to 10ml

[0025] The preparation method is:

[0026] Add 40 mg of sunitinib to 940 μl of 0.1N HCl, add 50 μl of Tween 80, add 5 ml of 50 mM citrate buffer, and 1 ml of 1% polyethylene glycol PEG-300, Finally, add water to 10 ml and shake vigorously to dissolve it; add 40 mg of Davicocinib to the above 40 mg of sunitinib / 10 ml.

Embodiment 2

[0028] The formula is as follows:

[0029] Sunitinib 10mg

[0030] Davacosini 40mg

[0031] 1N HCl 940 µl

[0032] Tween 80 50 microliters

[0033] 5 mL of 50 mM citrate buffer

[0034] 1% polyethylene glycol PEG-300 1ml

[0035] Sterile water Add to total volume to 10ml

[0036] The preparation method is:

[0037] Add 10 mg of sunitinib to 940 μl of 0.1N HCl, add 50 μl of Tween 80, add 5 ml of 50 mM citrate buffer, and 1 ml of 1% polyethylene glycol PEG-300, Finally, add water to 10 ml and shake vigorously to dissolve it; add 40 mg of Davicocinib to the above 10 mg of sunitinib / 10 ml.

Embodiment 3

[0039] The formula is as follows:

[0040] Sunitinib 70 mg

[0041] Davacosini 40mg

[0042] 1N HCl 940 µl

[0043] Tween 80 50 microliters

[0044] 5 mL of 50 mM citrate buffer

[0045] 1% polyethylene glycol PEG-300 1ml

[0046] Sterile water Add to total volume to 10ml

[0047] The preparation method is:

[0048]Add 70 mg of sunitinib to 940 μl of 0.1N HCl, add 50 μl of Tween 80, add 5 ml of 50 mM citrate buffer, and 1 ml of 1% polyethylene glycol PEG-300, Finally, add water to 10 ml and shake vigorously to dissolve it; add 40 mg of Davicocinib to the above 70 mg of sunitinib / 10 ml.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Aiming at the prior art, the invention aims to provide an anticancer composition based on an anti-angiogenesis medicine. The anticancer composition comprises a vascular endothelial growth factor receptor protein kinase inhibition medicine, namely a VEGFR inhibition medicine; and furthermore, according to the characteristic of a molecular passageway, a targeted medicine deoxyverrucosidin and a medically accepted carrier or excipient thereof are selected to be combined with the VEGFR inhibition medicine and a medically accepted carrier or excipient thereof, so that the problem of medicine resistance of the VEGFR inhibition medicine is fundamentally solved; and the effect of treating cancers is greatly enhanced.

Description

technical field [0001] The present invention generally relates to the field of tumor treatment, and more specifically, provides a pharmaceutical composition with synergistic or additive antitumor effects. Background technique [0002] Renal cell carcinoma (RCC) originates from the epithelial cells of the kidney. The cause of the disease is still unclear, and there is no early warning. Most patients with renal cell carcinoma are treated with surgery, but more than 50% of them have metastasis or postoperative recurrence at the time of diagnosis. The average survival time for metastatic kidney cancer is 13 months. RCC is generally insensitive to chemotherapy and radiotherapy. Before targeting receptor protein kinases (RTKs), metastatic RCC could only be treated with the cytokines interferon-α (IFNα) or interleukin-2. However, the effectiveness of these agents is low (<10%). At the same time, it will produce greater toxicity. However, in recent years, the treatment of ki...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/404A61P35/00A61K31/366
Inventor 朱曙东
Owner 朱曙东
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap